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ABSTRACT 
Objective: To define values of normalized brain volume (NBV) that can be categorized 
as low, medium or high, according to baseline characteristics of RRMS patients. 
Methods: Expected-NBV (eNBV) was calculated for each patient based on age, 
disease duration, sex, baseline EDSS and T2-lesion volume, entering these variables 
into a multiple regression model run on 2342 RRMS patients (pooled 
FREEDOMS/FREEDOMS-II population).According to the difference between their 
observed NBV and their eNBV, patients were classified as having low-NBV, medium-
NBV or high-NBV. We evaluated whether these NBV-categories were clinically 
meaningful by assessing correlation with disability worsening. 
Results: The distribution of differences between observed NBV and eNBV was used to 
categorize patients as having low-, medium- or high-NBV. Taking the high-NBV-group 
as reference, the HRs for 2-year disability worsening, adjusted for treatment effect, were 
1.23 (95%CI 0.92;1.63, p=0.16) for the medium-NBV and 1.75 (95%CI 1.26;2.44, 
p=0.001) for the low-NBV. The predictive value of NBV-groups was preserved over 4 
years. Treatment effect appeared more evident in low-NBV patients (HR=0.58) than  in 
medium-NBV (HR=0.72) and in high-NBV (HR=0.80) patients, but the difference was 
not significant (p=0.57). 
Conclusions: RRMS patients can be categorized into disability risk-groups based on 
individual eNBV-values according to baseline demographics and clinical characteristics.  
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INTRODUCTION 
Magnetic resonance imaging (MRI) derived measures of brain volume (BV) can be used 
to assess overall tissue damage in relapsing-remitting multiple sclerosis (RRMS).1-4 In 
RRMS patients, brain volume loss (BVL) has been proven to occur throughout the 
disease course, including the early stages, and progresses at a rate considerably higher 
than that of healthy adults.5-10 Recent work has defined relevant threshold values to 
discriminate pathological vs. physiological BVL rates in patients with RRMS,11 and has 
demonstrated the relevance of BVL as a measure of damage,12 with a proposal to 
include BVL in composite measures assessing RRMS disease activity.13 
Many studies have shown that baseline BV and the rate of BVL correlate with disability 
worsening and are also predictive of future disability.14-17 Also brain atrophy have been 
shown to be correlated in MS patients to cognitive impairment 18-19, employment status20 
and quality of life21 . Whereas the correlation between low brain volumes and disability 
worsening in patients with RRMS has been demonstrated at a group level, it is more 
difficult to establish at the individual level whether the volume of the brain measured in a 
single patient can be considered low or high. In this post-hoc analysis, we evaluated the 
possibility of defining individualized values for BV normalized for head size (NBV) to 
classify an individual patient as having a low or a high volume of the brain according to 
the demographic characteristics and the disease status of the individual subject. We 
then evaluated this classification by testing its ability to predict -on-study disability 
worsening. 
MATERIALS AND METHODS 
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Standard protocol approvals, registrations, and patient consents 
The FREEDOMS and FREEDOMS II trials (ClinicalTrials.gov identifiers: NCT00289978 
and NCT00355134, respectively) and their extensions were conducted in accordance 
with the International Conference on Harmonization Guidelines for Good Clinical 
Practice and the ethical principles of the Declaration of Helsinki.18, 19 The ethics 
committees and institutional review boards of all participating centers approved the 
study protocols. All participants provided written informed consent.20, 21 
Patients and study design 
The study design and inclusion/exclusion criteria of the FREEDOMS and FREEDOMS II 
trials have been previously described.20, 21 Briefly, the studies included RRMS patients 
(diagnosed according to the revised McDonald criteria22), aged 18–55 years who had a 
score of 0–5.5 on the Expanded Disability Status Scale (EDSS) and one or more 
documented relapses in the previous year or two or more relapses in the previous 2 
years. The eligible patients were randomized (1:1:1) to receive fingolimod 0.5 or 1.25 
mg/day, or placebo for 2 years.20, 21 All patients who completed the 24-month 
FREEDOMS/FREEDOMS II trial were eligible for the extension. Following FDA 
approval of fingolimod 0.5 mg dose, all patients receiving fingolimod 1.25 mg in study 
extensions were switched to fingolimod 0.5 mg. The extension phase continued until the 
umbrella safety extension study (ClinicalTrials.gov identifier, NCT01201356) opened for 
enrollment for patients who participated in all completed fingolimod studies.23, 24 
Assessments 
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Standardized neurological assessments, including determination of EDSS were 
conducted at baseline and every 3 months. MRI scans were obtained at baseline, 
months 6, 12, and 24 or at the end of the study, if the patient discontinued the study 
prematurely.20, 21 MRI lesion activity and BVL were assessed by a central reading site 
(Medical Image Analysis Center, Basel, Switzerland) that remained blinded for clinical 
data and randomization. MRI protocols and analysis methods have been detailed 
elswhere20,21 
Outcome measures 
The NBV was assessed at baseline using Structural Image Evaluation using 
Normalization of Atrophy, Cross-sectional (SIENAX).25 Disability worsening was defined 
as an increase in the EDSS score of ≥1 point sustained for ≥3 months (1.5 points if 
baseline EDSS = 0). 
Statistical analysis 
The analysis was run in two separate steps. In step 1, a cross-sectional analysis of 
baseline data was performed. Baseline factors that are correlated with baseline NBV 
were assessed for the pooled dataset from FREEDOMS and FREEDOMS II trials. A 
multivariate linear regression analysis, including age, sex, disease duration, EDSS, T2 
lesion volume (T2LV) and trial indicator (reperesenting the studies), was performed and 
the partial correlation coefficient of each factor (adjusted for all the other variables) with 
NBV was estimated. Variables with a skewed distribution (T2LV and disease duration) 
were transformed in three ordered groups defined by the tertiles of their distribution. 
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Age and EDSS score were treated as continuous variables, whereas sex and trial were 
categorical variables. The “trial” effect was estimated and compared to the residual 
variability of NBV (after adjusting the regression model for all the other baseline 
characteristics) to understand the comparability of the NBV measure between the two 
trials, adjusting for the different population characteristics. The trial effect on NBV was 
evaluated by using the greatest standardized mean difference (Cohen’s d) between a 
model including and excluding the trial effect. The trial effect can be considered 
negligible if Cohen’s d<0.20. Then, for each individual patient, an expected NBV (eNBV) 
according to individual baseline characteristics was calculated using the coefficients 
from the regression model, according to the linear formula: 
eNBV = a + b*T2LV + c*EDSS + d*Age + e*MS duration+ f*Male sex 
Where a is a constant and b, c, d, e, f are the partial coefficients estimated by the 
regression model. 
The difference between the observed NBV and the expected (eNBV)-value from the 
statistical model for each patient indicates whether the patient has a NBV higher or 
lower than expected (according to demographic and disease status). 
Based on the distribution of these differences, patients were categorized into three 
groups: Low-NBV for patients for whom the NBV was more than 1 SD below the eNBV, 
medium-NBV for patients for whom the NBV was within 1 SD from the eNBV, and high-
NBV for patients for whom the NBV was more than 1 SD above the eNBV.  
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In step 2, the prognostic values of the three defined NBV groups on disability (EDSS) 
change over 2 years were evaluated in the placebo-treated patients and in the overall 
population, adjusting for treatment effect. In both the FREEDOMS and FREEDOMS II 
trials, baseline characteristics were similar between the fingolimod 0.5 mg and 1.25 mg 
groups and, the two doses of fingolimod showed similar results across all efficacy 
outcomes (relapse rates, clinical disability worsening, and focal MRI lesion activity and 
brain volume loss). Hence, the current analysis was simplified by pooling the fingolimod 
0.5 mg and 1.25 mg groups (presented together as the fingolimod group). The 
prognostic value of the NBV was also evaluated on the whole cohort (patients originally 
randomized to placebo and fingolimod arms) over the 4-year extension period. Finally, a 
differential fingolimod effect as compared to placebo according to the different baseline 
NBV groups was assessed. 
The impact of the baseline NBV category, on the cumulative risk of 3-month confirmed 
disability progression (CDP) was analyzed using a Cox model. The fingolimod treatment 
effect on CDP for each baseline NBV category was evaluated by a treatment by group 
interaction test. The difference in the probability of worsening according to baseline 
NBV in placebo- and fingolimod-treated patients was displayed using Kaplan–Meier 
plots. 
RESULTS 
NBV at baseline estimated from the patient’s demographics and disease 
characteristics 
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Complete MRI and clinical baseline data were available for 2342 patients from the 
pooled intent-to-treat populations from FREEDOMS (N=1267), and FREEDOMS II 
(N=1075) studies. Table 1 reports the baseline characteristics of the patients included in 
this analysis. The overall baseline average NBV (±SD) was 1518 (±84) cm3 and was 
similar between the FREEDOMS (1514 [±85] cm3) and FREEDOMS II (1521 [±83] cm3) 
populations, and the distributions were nearly superimposable. T2LV, EDSS, age, 
disease duration, and sex showed significant correlations with NBV (p<0.001; for all; 
Table 2).  
The eNBV according to each patient characteristic can be calculated as: 
eNBV = 1763 - 34.6*T2LV - 8.2*EDSS - 3.3*Age - 10.8*MS duration - 23.4*Male sex 
The numerical details for the eNBV calculation are reported (Table 2), with examples of 
the calculation of eNBV for patients with different baseline and disease characteristics 
(Figure 1). The R2 value of the model was 36% indicating that the variables included 
were able to account for 36% of the variance in baseline NBV among patients. 
The distribution of the differences between the observed NBV and eNBV (calculated for 
each patient) is shown in (Figure 2a). The SD of this distribution was 67 cm3 and 
represented the between-patient variability in NBV not accounted for by the examined 
characteristics. The average NBV (adjusted for all the other baseline factors) was 14 
cm3 higher in FREEDOMS II than in FREEDOMS (p<0.001) indicating significant trial 
effect. However, since the greatest standardized mean difference of model residuals 
between individual studies (Cohen’s d) was 0.13 (<0.20), the trial effect was considered 
Sormani 8 
 
negligible as compared to the variability of NBV between patients and was not included 
in the calculation of the eNBV for each patient. 
The distribution of NBV differences from expected values (using 1 SD [67cm3] as the 
distance from the expected value) was used to categorize the patients in the low-NBV, 
medium-NBV and high-NBV groups. 
 Low NBV: NBV< eNBV − 67cm3 
 Medium NBV: eNBV − 67cm3 ≥ NBV ≤ eNBV + 67 cm3 
 High NBV: NBV > eNBV + 67 cm3 
According to this criterion, 365 patients (15.5%) were categorized as having low-NBV, 
1610 (69%) as having medium-NBV, and 367 (15.5%) as having high-NBV (Figure 2b). 
As the classification is individualized according to each patient’s demographic and 
disease characteristics at baseline (Figure 1), the same value of NBV can result in a 
different classification depending on the subject’s characteristics. For example, an NBV 
of 1500 cm3 would classify a young, non-disabled male patient with a low T2LV and a 
short disease duration in the low-NBV group, whereas the identical 1500 cm3 NBV 
value in an elderly, highly disabled patient with a high T2LV and a long disease history, 
would fall into the high-NBV group (Figure 1). 
Prognostic value of the proposed NBV categories for predicting disability 
worsening 
The impact of the categorization according to baseline NBV, adjusted for all the other 
relevant characteristics in the model, on the cumulative risk of 3-month CDP over 2 
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years is shown in Table 3 and Figure 3. The probability of 2-year confirmed disability 
worsening, after adjusting for treatment effect, was associated with the NBV 
categorization (p=0.002). Taking the high-NBV group as a reference, the hazard ratios 
(HRs) for the medium-NBV and low-NBV groups were 1.23 (95% CI 0.92;1.63, p = 0.16) 
and 1.75 (95% CI 1.26;2.44, p = 0.001), respectively. In placebo-treated patients, the 
proportion of patients with disability worsening was 20% (standard error [SE] 4%) in the 
high-NBV group; 25% (2%) (HR = 1.30, 95% CI 0.83;2.05, p=0.25) in the medium-NBV 
group; and 37% (5%) (HR = 2.13, 95% CI 1.26;3.61, p=0.005) in the low-NBV group. 
The corresponding values in the fingolimod-treated patients were 16% (2%), 19% (1%), 
and 23% (3%), respectively (Figure 3a).  
The treatment effect tended to be more evident in patients in the low-NBV group (HR = 
0.58, 95% CI 0.38;0.88) than in patients in the medium-NBV (HR = 0.72, 95% CI 
0.57;0.90) and in the high-NBV (HR=0.80, 95% CI 0.47;1.36) groups. However, the 
treatment effect was not significantly different across the three NBV groups since the p-
value for interaction was not significant (p = 0.57). 
A consistent pattern was also observed for cumulative risk of 6-month CDP over 2 
years, although fewer events occurred (data not shown). Furthermore, the prognostic 
value of NBV in predicting disability worsening was confirmed over longer periods, up to 
4 years, using data from the FREEDOMS and FREEDOMS II extension studies (Figure 
3b). 
DISCUSSION 
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MS is a complex disease of the central nervous system. Although macroscopic, 
inflammatory lesions are the most evident aspect of MS pathology, a widespread 
pathology also occurs.1 Global brain atrophy, which starts at the earliest stage of MS 
and progresses through disease course, is the expression of such diffuse tissue 
pathology.10 While quantification is routinely used for MRI-derived assessment of 
lesions in clinical practice to guide clinical decisions22 this is much less common for 
MRI-derived cross-sectional and longitudinal measures of atrophy. Including BVL as a 
cumulative measure of widespread pathology of the CNS in RRMS, should provide a 
more comprehensive and balanced assessment of the patient disease course. 
Brain volume in MS depends on many demographic (age, sex) and clinical 
characteristics (disease duration, disability level etc.).17 In this study, we quantified the 
distribution of NBV in a large cohort of RRMS patients, adjusting for the relevant 
baseline characteristics in order to identify the NBV values of those subjects that are 
“far” from their expected values. By using this methodology, patients are classified as 
having a high, medium or low NBV relative to all other patients with similar baseline 
characteristics. We demonstrated that it is possible to define values for each individual 
patient of what we called “expected NBV” based on adjustments for disease-relevant 
covariates (T2LV, age, EDSS, disease duration, and sex) and proposed a formula 
which can be used to calculate the NBV cutoff for an individual patient. The putative 
clinical relevance of this was that, based on these individualized values of NBV, it is 
possible to identify patients who are at a higher risk for future disability worsening. 
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The present analysis represents the first attempt to define individual cutoff values of 
brain volume, acknowledging the patients baseline characteristics. Our results suggest 
that the classification of patients into low, medium, and high NBV categories allows for a 
better characterization of the patient risk of future disability worsening and may inform 
individual management through the course of the disease. It needs to be stressed, 
however, that the approach used here has several limitations that restricts its utility in 
clinical practice26. These include lack of standardization and varying quality in the MRI 
acquisition, as well as potential for inaccurate image post-processing. For example, 
data reported here might be different with different MRI acquisitions (e.g., field strength, 
voxel size, type of sequence, etc.) or different imaging analysis (e.g., software packages 
different from SIENAX, different imaging reading site, etc). These can be relevant 
sources of error that can affect the measurement estimation. Additionally, generic 
factors, such as lifestyle habits, genetic load, and concomitant pathologic conditions 
may also affect BV measurements and need to be taken into account when interpreting 
brain atrophy, particularly in the single patient assessment. Despite the above 
limitations, progress in computational technologies allows to expect a more convincing 
clinical use of MRI-based brain volumetry in a number of neurological disorders, 
including RRMS.27 Further studies are needed on independent datasets to evaluate 
whether cutoffs need to be re-calibrating after correcting for different MRI acquisition 
protocols  and analysis pipelines.  
In the present study, the overall baseline average NBV was very similar between the 
two large, multi-center clinical datasets (FREEDOMS and FREEDOMS II) with 
distributions that were nearly superimposable. This is indicative of a great homogeneity 
Sormani 12 
 
in the NBV values, which is of paramount importance for the validity of the results. To 
create common cut-offs, in fact, there must be no systematic differences in NBV when 
measured in different settings. For this reason, these results need to be validated in 
other datasets to understand whether the same methodology and the same 
individualized values of NBV can be extended to other patient populations, especially to 
those beyond controlled clinical trials. Moreover, it is important to re-emphasize that the 
present analysis was based on the NBV calculations using SIENAX and cannot be 
extended to other methods of BVL assessment. Finally, although SIENAX is a widely 
used, standard method in clinical trials, its use in clinical practice on individual patients 
might be challenging and requires experienced personnel to perform accurate 
measurements.28 
Patients included in clinical trials are usually active inflammatory patients, due to the 
inclusion criteria aimed at enriching patients for activity at baseline. Whereas baseline 
inflammatory activity can affect the rate of brain volume change over time, the baseline 
value of NBV is much less affected by this and did not result associated to MRI activity 
assessed by gadolinium enhancement in this large dataset. More in general, however,, 
NBV is a measure of the brain volume loss occurred in the given patient until the time of 
the measurement, and for this is less intrinsically dependent of the inflammatory activity 
at the time, but rather dependent on the overall disease burden.  In that respect, the 
formula used to calculate the expected NBV included the T2 lesion burden, as 
expression of the overall focal pathology that can be associated to the baseline brain 
volume. As a consequence, the findings reported here can be generalizable to a typical 
clinic population of MS patients, composed of a mixture of active and inactive patients.   
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When discussing brain volume, brain reserve and cognitive reserve also need to be 
considered. Several studies have indicated that both, brain reserve and cognitive 
reserve, may serve as a buffer against future cognitive impairment.29-31 Our findings 
generally support this concept, as we showed that individuals with a higher-than-
expected NBV had a better prognosis for disability worsening over 2 and 4 years, than 
those with a lower NBV. This suggests that a window of opportunity exists, wherein 
therapeutic interventions can be the most effective in delaying disease worsening 
implying that an early intervention with an effective disease-modifying therapy may be 
linked to a more favorable long-term outcome.  
A number of studies have consistently shown a close correlation between BVL and 
disability worsening, particularly in the long-term.14, 17, 32 A recent post hoc analysis of 
data from the fingolimod phase III trials provided evidence that NBV at baseline was the 
strongest predictor of disability in RRMS patients and the correlation of BVL with 
worsening disability was stronger over four years than in the first two years on study.17 
The prognostic value of brain atrophy rates in predicting long term disability has also 
been demonstrated in other studies.14, 32 A large multicenter study reported that whole 
and central brain atrophy over one year can predict EDSS scores at 10 years in a 
heterogeneous group of MS patients.14 In a follow-up study reassessing RRMS patients 
from a phase III trial of interferon β-1a, brain atrophy rate was found to be the best MRI 
predictor of disability status at the 8-year follow-up.32 Consistent with these findings, we 
observed that the baseline NBV values in individual patients predicted disability 
worsening over 2 to 4 years. 
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In summary, we propose a methodology to calculate quantitative reference values for 
single-point NBV measurements, that allows to identify patients having a lower value of 
brain volume than that expected according to their clinical and demographic profile. This 
classification can be used to assign RRMS patients to distinct risk groups regarding 
future disability worsening and may help physicians to identify and appropriately treat 
patients at a higher risk of disability worsening.  
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